Fresenius Medical Care (FMS) Executes on Strategic Portfolio Optimization Program, Announces Key Transactions
Get Alerts FMS Hot Sheet
Join SI Premium – FREE
Fresenius Medical Care (NYSE: FMS) today announced updates from transactions in 2023 as part of the Company's ongoing Portfolio Optimization Program. Refocused on businesses and markets with the best strategic fit and greatest scale and sustainable profitable growth potential, Fresenius Medical Care continues exiting unsustainable markets, divesting noncore and dilutive assets and prioritizing deleveraging as part of a disciplined and stringent approach to capital allocation.
"We have made significant progress in our Portfolio Optimization Program efforts with the recent divestitures, which will further simplify Fresenius Medical CareĀ“s portfolio and allow even greater management focus in 2024. The execution against our strategic plan will additionally support the improvement of our leverage ratio in 2024," said
Since announcing its intent to optimize its product portfolio, divest noncore business assets and exit certain markets as part of its strategic plan, Fresenius Medical Care has now signed and closed transactions exiting its
In aggregate, the three divested assets include 127 facilities, more than 4,500 employees and more than 10,000 dialysis patients. The three divestments represented in 2022 a total proforma revenue of around
Depending on exchange rates the Company expects net proceeds of around
All assets currently under review as part of the Portfolio Optimization would, if executed by the end of 2025, negatively impact 2025 revenue by
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FSD Pharma (HUGE) Issues Corporate Update
- JFrog Ltd. (FROG) to Acquire Qwak AI, Reaffirms 2024 Guidance
- CrowdStrike Holdings Inc. (CRWD) Exceeds $1B in Sales with CDW
Create E-mail Alert Related Categories
Corporate News, Guidance, Mergers and AcquisitionsRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!